NKX2-2 Gene
NK2 Homeobox 2: A Key Transcription Factor in Neuroendocrine and Pancreatic Development
Gene Information Card
| Symbol | NKX2-2 |
|---|---|
| Full Name | NK2 Homeobox 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 20p11.22 |
| NCBI Gene ID | 4821 ncbi.nlm.nih.gov/gene/4821 |
| Ensembl ID | ENSG00000125868 |
| UniProt ID | O95096 |
| OMIM ID | 604612 |
| HGNC ID | 7836 |
| Aliases | NKX2.2, NKX2B |
Description
NKX2-2 encodes a homeodomain-containing transcription factor essential for the development of the central nervous system and pancreatic islet cells. It plays a critical role in specifying neuronal subtypes and regulating insulin gene expression. Mutations and altered expression of NKX2-2 are implicated in neuroendocrine tumors and diabetes.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Neuroendocrine tumors (e.g., insulinoma, small cell lung carcinoma) | Overexpression or aberrant activation of NKX2-2 promotes tumorigenesis by maintaining a neuroendocrine phenotype. | PMID: 23431173, COSMIC |
| Maturity-onset diabetes of the young (MODY) | Loss-of-function mutations impair pancreatic beta-cell development and insulin secretion. | PMID: 17999361, ClinVar |
| Congenital hyperinsulinism | Gain-of-function mutations lead to inappropriate insulin secretion. | PMID: 25683116, ClinVar |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Pancreas | 12.5 | Medium |
| Brain | 8.3 | Medium |
| Lung | 3.1 | Low |
| Small intestine | 2.0 | Low |
| Thyroid | 1.5 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| NCI-H69 (small cell lung cancer) | 45.2 | High expression |
| INS-1 (rat insulinoma) | 38.7 | High expression |
| HeLa | 0.5 | Very low |
| HEK293 | 0.3 | Very low |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.425C>T (p.Pro142Leu) | Missense | <0.1% | Loss of DNA-binding activity; associated with MODY |
| c.518G>A (p.Arg173His) | Missense | <0.1% | Gain of function; associated with congenital hyperinsulinism |
| c.1A>G (p.Met1?) | Start loss | <0.1% | Loss of function; likely pathogenic |
Mutation functional classification
Loss of Function (LOF)
Mutations that disrupt DNA binding or nuclear localization, leading to reduced transcriptional activation of target genes (e.g., insulin).
Gain of Function (GOF)
Mutations that enhance transcriptional activity or stability, resulting in increased insulin expression and hyperinsulinism.
Dominant Negative (DN)
Not well documented for NKX2-2; most reported mutations are either loss- or gain-of-function.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Pancreatic beta-cell development (Reactome: R-HSA-210745)
• Transcriptional regulation of insulin (KEGG: hsa04930)
Protein Summary
NKX2-2 is a 273-amino acid protein containing a homeobox DNA-binding domain. It functions as a transcriptional repressor or activator depending on context, and is critical for specifying the fate of pancreatic beta-cells and certain neuronal subtypes. The protein interacts with other transcription factors such as PDX1 and NEUROD1 to regulate insulin gene expression.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| No Data | ||||
